These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases. Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963 [TBL] [Abstract][Full Text] [Related]
24. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229 [TBL] [Abstract][Full Text] [Related]
25. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210 [TBL] [Abstract][Full Text] [Related]
26. Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC. Kunimasa K; Nishino K; Sato Y; Mori M; Ihara S; Suzuki H; Nagatomo I; Kumagai T; Morishima T; Imamura F Sci Rep; 2022 Aug; 12(1):13544. PubMed ID: 35941190 [TBL] [Abstract][Full Text] [Related]
27. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247 [TBL] [Abstract][Full Text] [Related]
28. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. Lee K; Kim D; Yoon S; Lee DH; Kim SW Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716 [TBL] [Abstract][Full Text] [Related]
29. A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC Cancer Res Treat; 2021 Jan; 53(1):93-103. PubMed ID: 32972042 [TBL] [Abstract][Full Text] [Related]
30. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999 [TBL] [Abstract][Full Text] [Related]
31. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis. Li ZX; Zhao W; Sun Q; Tang MS; Xia QJ; Dong MS Clin Transl Oncol; 2020 Jun; 22(6):892-899. PubMed ID: 31538306 [TBL] [Abstract][Full Text] [Related]
33. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T Thorac Cancer; 2019 Oct; 10(10):1879-1884. PubMed ID: 31414729 [TBL] [Abstract][Full Text] [Related]
35. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987 [No Abstract] [Full Text] [Related]
36. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259 [TBL] [Abstract][Full Text] [Related]